



RECEIVED

MAY 25 2001

TECH CENTER 1600/2900

Attorney Docket No.: A-68970-1/DJB/RMS/DCF

#3  
GAV-1645  
Box - Seq.  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JIAN-BING FAN

Serial No. 09/785,514

Filed: February 16, 2001

For: PARALLEL GENOTYPING OF  
MULTIPLE PATIENT SAMPLES

Examiner: NOT YET ASSIGNED

Group Art Unit: 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on:

Dated:

5.16.01

Signed

Christine P. Peters  
Christine P. Peters

AMENDMENT RE: SEQUENCE LISTING

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This Amendment re: Sequence Listing is being submitted in anticipation of receiving a Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Prior to substantive examination of the present case, Applicant offers the following amendments and remarks.

The Commissioner is authorized to charge any fees, including extension fees, which may be required, or credit any overpayment to Deposit Account No. 06-1300 (Our Order No. A-68970-1/DJB/RMS/DCF).

Please amend the application as follows and to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures in adherence with rules 37 C.F.R. § 1.821-1.825:

Serial No.: 09/785,514  
Filed: February 16, 2001

RECEIVED  
MAY 25 2001  
TECH CENTER 1600/2900

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 4, line 20, with the following rewritten paragraph:

– Figure 4 is an example of an image of FAM-labeled oligonucleotides hybridized to bead immobilized target analytes. A depicts positive control data obtained with the following oligonucleotide: FAM-CCAAGGGTGTGGTGAAAGAT (20-mer) (SEQ ID NO:1). B. depicts negative control data obtained with the following oligonucleotide: FAM-TCCTCCAGACCGCAGGC (17-mer) (SEQ ID NO:2) .–

On page 51, immediately preceding the claims, insert the enclosed text entitled "SEQUENCE LISTING".

REMARKS

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made."


These amendments are made in adherence with 37 C.F.R. § 1.821-1.825. This amendment is accompanied by a floppy disc containing the above named sequence, SEQUENCE ID NUMBERS 1-2, in computer readable form, and a paper copy of the sequence information. The computer readable sequence listing was prepared through use of the software program "Patent-In" provided by the PTO. The information contained in the computer readable disk is identical to that of the paper copy. This amendment contains no new matter. Applicant submits that this amendment, the accompanying computer readable sequence listing, and the paper copy thereof serve to place this application in a condition of adherence to the rules 37 C.F.R. § 1.821-1.825.

**Serial No.:** 09/785,514  
**Filed:** February 16, 2001

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

FLEHR HOHBACH TEST  
ALBRITTON & HERBERT LLP

A handwritten signature in black ink, appearing to read "David C. Foster", written over a horizontal line.

David C. Foster  
Reg. No. 44,685

Four Embarcadero Center, Suite 3400  
San Francisco, CA 94111-4187  
Telephone: (415) 781-1989